Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 18

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 18
---
, California 94111.(2)Based solely on a Schedule 13G/A filed with the SEC on February 12, 2024. The Vanguard Group, or Vanguard, is deemed to be the beneficial owner of 5,599,917 shares of common stock, with respect to which it reported shared voting power over 38,887 shares, sole dispositive power over 5,497,393 shares and shared dispositive power over 102,524 shares. The address of Vanguard is 100 Vanguard Blvd., Malvern, PA 19355.(3)Based solely on a Schedule 13G/A filed with the SEC on January 25, 2024 by BlackRock, Inc., or BlackRock, and certain of its subsidiaries. BlackRock is deemed to be the beneficial owner of 4,962,237 shares of common stock, with respect to which it reported sole voting power over 4,824,374 shares and sole dispositive power over 4,962,237 shares. The address of BlackRock is 50 Hudson Yards, New York, NY 10001.(4)Based solely on a Schedule 13G/A filed with the SEC on February 14, 2025. BB Biotech AG, or BB Biotech, and its wholly-owned subsidiary Biotech Target N.V., or Biotech Target, share voting and dispositive power over 3,515,150 shares of common stock. The address of BB Biotech is Schwertstrasse 6,CH-8200Schaffhausen, Switzerland and the address of Biotech Target is Ara Hill Top Building, UnitA-5,Pletterijweg Oost 1, Curacao.(5)Includes shares of common stock held by the Foster Family Revocable Trust.12

#### DELINQUENT SECTION 16(a) REPORTS
Under Section 16(a) of the Exchange Act, directors, executive officers, our principal accounting officer and beneficial owners of 10% or more of our common stock, or reporting persons, are required to report to the SEC on a timely basis the initiation of their status as a reporting person and any changes with respect to their beneficial ownership of our common stock. Based solely on our review of copies of such forms that we have received, or written representations from reporting persons, we believe that during the fiscal year ended December 31, 2024, all reporting persons complied with all applicable filing requirements, except with respect to Form 4 filings by Dr. Fouse, Mr